Cargando…
Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity
Exebacase (CF-301), a novel, antistaphylococcal lysin (cell wall hydrolase) is the first agent of this class to enter late-stage clinical development (phase 3, NCT04160468) for the treatment of Staphylococcus aureus bacteremia, including right-sided endocarditis. A multilaboratory Clinical and Labor...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218745/ https://www.ncbi.nlm.nih.gov/pubmed/33910968 http://dx.doi.org/10.1128/JCM.03117-20 |
_version_ | 1783710808633507840 |
---|---|
author | Traczewski, Maria M. Ambler, Jane E. Schuch, Raymond |
author_facet | Traczewski, Maria M. Ambler, Jane E. Schuch, Raymond |
author_sort | Traczewski, Maria M. |
collection | PubMed |
description | Exebacase (CF-301), a novel, antistaphylococcal lysin (cell wall hydrolase) is the first agent of this class to enter late-stage clinical development (phase 3, NCT04160468) for the treatment of Staphylococcus aureus bacteremia, including right-sided endocarditis. A multilaboratory Clinical and Laboratory Standards Institute (CLSI) M23-defined tier 2 quality control (QC) study was conducted to establish exebacase QC ranges for a new reference broth microdilution method. S. aureus ATCC 29213 and Enterococcus faecalis ATCC 29212 were selected as reference QC strains. Broth microdilution MIC QC ranges for exebacase spanned 4 log(2) dilutions and contained 99.2% of the MIC results generated for the two reference strains. The QC ranges for exebacase were defined as 0.25 to 2 μg/ml and 8 to 64 μg/ml against S. aureus ATCC 29213 and E. faecalis ATCC 29212, respectively, and were approved by the CLSI Subcommittee on Antimicrobial Susceptibility Testing. These QC ranges established for use with the reference broth microdilution method developed for exebacase susceptibility testing will ensure the test performance and accuracy of results generated during clinical development. |
format | Online Article Text |
id | pubmed-8218745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-82187452021-12-18 Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity Traczewski, Maria M. Ambler, Jane E. Schuch, Raymond J Clin Microbiol Bacteriology Exebacase (CF-301), a novel, antistaphylococcal lysin (cell wall hydrolase) is the first agent of this class to enter late-stage clinical development (phase 3, NCT04160468) for the treatment of Staphylococcus aureus bacteremia, including right-sided endocarditis. A multilaboratory Clinical and Laboratory Standards Institute (CLSI) M23-defined tier 2 quality control (QC) study was conducted to establish exebacase QC ranges for a new reference broth microdilution method. S. aureus ATCC 29213 and Enterococcus faecalis ATCC 29212 were selected as reference QC strains. Broth microdilution MIC QC ranges for exebacase spanned 4 log(2) dilutions and contained 99.2% of the MIC results generated for the two reference strains. The QC ranges for exebacase were defined as 0.25 to 2 μg/ml and 8 to 64 μg/ml against S. aureus ATCC 29213 and E. faecalis ATCC 29212, respectively, and were approved by the CLSI Subcommittee on Antimicrobial Susceptibility Testing. These QC ranges established for use with the reference broth microdilution method developed for exebacase susceptibility testing will ensure the test performance and accuracy of results generated during clinical development. American Society for Microbiology 2021-06-18 /pmc/articles/PMC8218745/ /pubmed/33910968 http://dx.doi.org/10.1128/JCM.03117-20 Text en Copyright © 2021 Traczewski et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Bacteriology Traczewski, Maria M. Ambler, Jane E. Schuch, Raymond Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity |
title | Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity |
title_full | Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity |
title_fullStr | Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity |
title_full_unstemmed | Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity |
title_short | Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity |
title_sort | determination of mic quality control parameters for exebacase, a novel lysin with antistaphylococcal activity |
topic | Bacteriology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218745/ https://www.ncbi.nlm.nih.gov/pubmed/33910968 http://dx.doi.org/10.1128/JCM.03117-20 |
work_keys_str_mv | AT traczewskimariam determinationofmicqualitycontrolparametersforexebacaseanovellysinwithantistaphylococcalactivity AT amblerjanee determinationofmicqualitycontrolparametersforexebacaseanovellysinwithantistaphylococcalactivity AT schuchraymond determinationofmicqualitycontrolparametersforexebacaseanovellysinwithantistaphylococcalactivity |